CDSCO Expert Panel Mandates Protocol Revisions for Glimepiride-Linagliptin Combination Phase III Trial
Key Insights
The Central Drugs Standard Control Organisation (search)'s Subject Expert Committee has recommended key modifications to Pure and Cure Healthcare (search)'s Phase III clinical trial protocol for their glimepiride-linagliptin fixed-dose combination tablets.
The panel mandated stricter exclusion criteria, requiring patients with fasting glucose levels of 200 mg/dl or higher to be excluded from the Type 2 diabetes study.
Enhanced monitoring protocols were recommended, including HbA1c assessments at baseline, 12 weeks, and 24 weeks, along with standardized patient self-monitoring of blood glucose levels.
The Central Drugs Standard Control Organisation (search)'s Subject Expert Committee has issued comprehensive recommendations for revising the Phase III clinical trial protocol of Pure and Cure Healthcare (search)'s glimepiride-linagliptin fixed-dose combination tablets, following their review of bioequivalence study data for the Type 2 diabetes treatment.
The expert panel's recommendations came after Pure and Cure Healthcare (search) presented their proposal along with bioequivalence study report and revised Phase III clinical trial protocol before the committee. The committee considered the bioequivalence study report for Glimepiride 1 mg/2 mg plus Linagliptin 5 mg/5 mg Tablets before making their determinations.
Key Protocol Modifications Required
The committee mandated four critical changes to the Phase III clinical trial protocol. First, the exclusion criteria must specify that patients with fasting glucose levels of 200 mg/dl or higher will be excluded from the study. This modification aims to ensure appropriate patient selection for the diabetes management trial.
Second, the protocol must include detailed procedures for capturing hypoglycemic episodes, a crucial safety consideration given the mechanism of action of the combination therapy. The committee emphasized the importance of comprehensive documentation of these potentially serious adverse events.
Enhanced Monitoring Requirements
The expert panel established a structured monitoring schedule requiring HbA1c assessments at three specific timepoints: baseline, 12 weeks, and 24 weeks. This glycemic control monitoring protocol will provide critical efficacy data throughout the study duration.
Additionally, the committee mandated that patients conduct periodic self-monitoring of blood glucose using a standard glucometer, with all readings properly recorded. This requirement ensures continuous glucose monitoring data collection beyond the scheduled clinical assessments.
Regulatory Pathway Forward
Following the committee's recommendations, Pure and Cure Healthcare (search) must submit the revised Phase III clinical trial protocol to CDSCO (search) for approval. Once CDSCO approves the modified protocol, the company will need to complete the Phase III clinical trial and submit the resulting data to CDSCO for further committee review.
Combination Therapy Mechanism
The glimepiride-linagliptin combination (search) represents a dual-mechanism approach to Type 2 diabetes management. Glimepiride, a sulfonylurea, helps lower blood glucose by stimulating insulin secretion from pancreatic beta cells (search), while linagliptin, a DPP-4 (search) inhibitor, improves glycemic control by increasing incretin (search) levels, thereby enhancing insulin release and decreasing glucagon levels.
The Subject Expert Committee's detailed deliberation and specific recommendations reflect the regulatory authority's commitment to ensuring robust clinical evidence for this oral anti-diabetic combination therapy before potential market approval.